Lymphoma, FollicularLymphoma, Non-HodgkinTazemetostatRituximab
Dr. Katisha T. Vance, MD
NPI1467526442PAC ID1658284294
- Medicare services, 2024
- 56,993
- Medicare patients, 2024
- 232
- Part D claims, 2024
- 3,548
- Clinical trials
- 4
- MIPS score, 2024
- 88
- Practice address
- 500 Office Park Dr, Mountain Brk, AL 35223
- Practice phone
- Call (205) 870-4783
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Birmingham Hematology Oncology Assoc
Mountain Brk, Alabama
Find Dr. Vance's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Katisha T. Vance is a hematologist and oncologist in Mountain Brk, Alabama
Dr. Vance practices at Birmingham Hematology Oncology Assoc in Mountain Brk, Alabama.
Dr. Vance's NPI, 1467526442, was assigned on November 20, 2006. Dr. Vance graduated from University of Alabama School of Medicine in 2000. Dr. Vance holds Alabama license 24465.
NPI and contact details
- NPI
- 1467526442NPI Registry (opens in a new tab)
- Medicare PAC ID
- 1658284294
- NPI enumeration date
- November 20, 2006
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Practice phone
- (205) 870-4783
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 52
- Medical school graduation
- 2000
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Practice Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Katisha T. Vance practices at Birmingham Hematology Oncology Assoc in Mountain Brk, Alabama
Dr. Vance's primary practice is Birmingham Hematology Oncology Assoc, at 500 Office Park Dr, Mountain Brk, AL 35223 in Jefferson County. The practice phone is (205) 870-4783.
- Birmingham Hematology Oncology Assoc500 Office Park Dr, Mountain Brk, AL 35223 · Jefferson CountyPhone(205) 870-4783
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dr. Katisha T. Vance is affiliated with 3 sites of care and 1 medical group
Dr. Vance's primary practice is Birmingham Hematology Oncology Assoc in Mountain Brk, Alabama. Dr. Vance is also affiliated with Baptist Health Princeton Hospital. The medical group on file is Alabama Oncology. Dmand AI also links Dr. Vance to 1 more group practice or clinic, named with a free account.
Birmingham Hematology Oncology AssocPrimary
Sources: NPPES NPI Registry (CMS); Dmand AI Practice Data; and Dmand AI Affiliation Data
Dmand AI tracks the EHR system at Dr. Katisha T. Vance's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vance practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Birmingham Hematology Oncology Assoc | Available with a free account |
| +2 more affiliated sites | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Vance practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Katisha T. Vance is one of 169 hematologists and oncologists in Alabama
Hematology and oncology is Dr. Vance's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Vance is licensed in Alabama.
Specialties and state licenses
- Hematology and oncology, AlabamaPrimary
Hematologists and oncologists near Dr. Vance
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Katisha T. Vance billed Medicare for 56,993 services in 2024
CMS data shows 56,993 Medicare services from Dr. Vance across 29 procedure codes in 2024, for 232 Medicare patients. Medicare paid $326,983 for them.
Medicare services, 202456,993
Medicare patients232
Paid by Medicare$326,983
Procedure codes29
Dr. Vance's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Other services
- 2023: 47,4302024: 35,31326%
- Drugs given in the office
- 2023: 11,8502024: 18,33055%
- Tests and treatments
- 2023: 1,7862024: 1,58211%
- Lab and pathology
- 2023: 7082024: 81315%
- Surgery
- 2023: 5102024: 57212%
- Office and hospital visits
- 2023: 4282024: 38311%
Where Dr. Vance's Medicare services took place, 2024
- In an office56,948100%
- In a facility450%
Dr. Vance compared with the Alabama median for hematologists and oncologists, 2024
- Dr. Vance
- Alabama median
- Medicare services
- 56,993vs 1,22446.6 times
- Medicare patients
- 232vs 28218% below
- Part D claims
- 3,118vs 8463.7 times
Medians across 162 hematologists and oncologists in Alabama with Dmand AI profiles that report each measure.
Dr. Vance's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Vance?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Vance and other hematologists and oncologists in Alabama.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Katisha T. Vance treated 232 Medicare patients in 2024, average age 73
CMS counts 232 Medicare patients who saw Dr. Vance in 2024. The largest group is 65 to 74, with 105 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Vance's median patient age at 71, with 70% women.
Medicare patients, 2024232
Average age73
Average risk score2.23
Also on Medicaid21%
Dr. Vance's Medicare patients by age, 2024
Dr. Vance's Medicare patients by sex, 2024
- Women14462%
- Men8838%
Chronic conditions among Dr. Vance's Medicare patients, 2024
- High blood pressure75%
- High cholesterol75%
- Arthritis56%
- Cancer52%
- Chronic kidney disease47%
- Diabetes47%
- Ischemic heart disease37%
- COPD28%
Share of Medicare patients with each condition. A patient can have several.
Dr. Vance's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 71
Patient panel by sex, all payers
- Women70%
- Men30%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Katisha T. Vance wrote 3,548 Medicare Part D claims in 2024
In 2024, Dr. Vance wrote 3,548 Medicare Part D claims for 435 patients. 84% of them were for generic drugs. CMS names the drug for 3,118 of them, across 67 drugs with 11 or more claims each, at $4,797,564 in total drug cost. In 2023, CMS named 3,025 claims across 70 drugs.
Part D claims, 20243,548
Drugs named by CMS67
Total drug cost$4.8M
Part D patients435
Dr. Vance's Part D claims by kind of drug, 2024
- Generic2,996 claims84%
- Brand-name and other552 claims16%
Dr. Vance's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Vance's Part D claims, 2024
- Opioids14%508 of 3,548 claims
- Antibiotics6%199 of 3,548 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 3,0252024: 3,1183%
Drugs named by CMS: 67 in 2024, 70 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Katisha T. Vance scored 88 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Vance for performance year 2024, reported as part of a group. Dr. Vance accepts Medicare assignment, so Medicare's approved amount is taken as full payment.
- Accepts Medicare assignment
- Yes
Dr. Vance's MIPS scores, performance year 2024
- 88of 100Final score
- 79.4of 100Quality
- 92of 100Promoting Interoperability
- 40of 100Improvement Activities
- 75of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Find hematologists and oncologists like Dr. Vance by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Katisha T. Vance has worked on 4 clinical trials
Dmand AI links Dr. Vance to 4 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Anemia, Sickle Cell, Lymphoma, Follicular and Lymphoma, Large B-Cell, Diffuse.
Clinical trials with Dr. Vance by phase
- NonePhase 1: no trials
- 2Phase 2: 2 trials
- 1Phase 3: 1 trial
- NonePhase 4: no trials
Conditions in Dr. Vance's trials
- Anemia, Sickle Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Triple Negative Breast Neoplasms
- Anemia, Hemolytic, Congenital
Investigators on the most trials with Dr. Vance
- Miguel A. Islas-Ohlmayer, MD2 shared trials
- John Scott Renshaw, MD2 shared trials
- Guillermo Abesada-Terk, MD1 shared trial
Recent clinical trials with Dr. Vance
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (opens in a new tab)
Active, not recruitingPhase 3
Lymphoma, Large B-Cell, DiffuseLymphoma, B-CellBrentuximab vedotinLenalidomideRituximab
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (opens in a new tab)
CompletedPhase 2
Triple Negative Breast NeoplasmsBreast NeoplasmsCDX-011Capecitabine
Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options (opens in a new tab)
No longer available
Anemia, Sickle CellAnemia, Hemolytic, CongenitalVoxelotor
Sources: ClinicalTrials.gov (National Library of Medicine); and Dmand AI Research Linkage
Dr. Katisha T. Vance received $13,095 in industry payments from 2016 to 2025
CMS Open Payments shows 617 general payments to Dr. Vance from 72 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 80% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,506.
General payments to Dr. Vance by program year, 2016 to 2025
General payments to Dr. Vance by kind, 2016 to 2025
$13.1Kin total
- Food and beverage$10,45580%
- Consulting fees$2,58020%
- Education$600%
Companies that paid Dr. Vance the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Katisha T. Vance graduated from University of Alabama School of Medicine
Dr. Vance graduated from University of Alabama School of Medicine in 2000.
- Medical school
Source: Dmand AI Professional Profile Data
Sources for Dr. Katisha T. Vance's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Primary practice, affiliations and health system | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice DataDmand AI Affiliation Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Clinical trials and co-investigators | ClinicalTrials.gov (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Katisha T. Vance
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Katisha T. Vance's NPI number?
Dr. Katisha T. Vance's NPI number is 1467526442. It was assigned on November 20, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Katisha T. Vance?
Dr. Katisha T. Vance is a hematologist and oncologist in Mountain Brk, Alabama. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Katisha T. Vance practice?
Dr. Vance practices at 500 Office Park Dr, Mountain Brk, AL 35223. Dr. Vance's primary practice is Birmingham Hematology Oncology Assoc in Mountain Brk, Alabama. Dmand AI also links Dr. Vance to 1 group practice or clinic.
What is Dr. Katisha T. Vance's office phone number?
The practice phone on file for Dr. Vance is (205) 870-4783.
What is Dr. Katisha T. Vance's medical license number?
Dr. Vance holds Alabama license 24465.
Which hospitals is Dr. Katisha T. Vance affiliated with?
Dr. Vance is affiliated with Baptist Health Princeton Hospital.
What medical group is Dr. Katisha T. Vance part of?
Dr. Vance is linked to Alabama Oncology.
Does Dr. Katisha T. Vance accept Medicare?
Yes. CMS data shows Dr. Vance billed Medicare for 56,993 services in 2024, and Dr. Vance accepts Medicare assignment.
What is Dr. Katisha T. Vance's MIPS score?
Dr. Vance's MIPS final score for performance year 2024 is 88 out of 100, reported as part of a group.
How many Medicare patients does Dr. Katisha T. Vance see?
CMS counts 232 Medicare patients who saw Dr. Vance in 2024, with an average age of 73.
Show 6 more questionsShow fewer questions
What services does Dr. Katisha T. Vance bill to Medicare?
In 2024, Dr. Vance's most billed Medicare services were medicare temporary code (Q0138), injected or infused drug (J0897) and injected or infused drug (J0881).
Where did Dr. Katisha T. Vance go to medical school?
Dr. Vance graduated from University of Alabama School of Medicine in 2000.
What drugs does Dr. Katisha T. Vance prescribe most?
In 2024 Medicare Part D data, Dr. Vance's most prescribed drugs by claims were Anastrozole, Hydrocodone-Acetaminophen and Ondansetron HCl.
Has Dr. Katisha T. Vance received payments from drug or device companies?
CMS Open Payments shows $13,095 in general payments to Dr. Vance from 72 companies from 2016 to 2025. The largest total came from Novartis Pharmaceuticals Corporation.
How long has Dr. Katisha T. Vance been practicing?
Dr. Vance graduated from medical school in 2000, 26 years ago.
Does Dr. Katisha T. Vance do research?
Dr. Vance has worked on 4 clinical trials.
Selling to hematology and oncology practices?
See hematologists and oncologists in Alabama by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card